Chronic Myelogenous Leukemia

Introduction And Epidemiology

Represents rare pediatric hematologic malignancy.
Accounts for 2-3% of all childhood leukemias,
Incidence exceptionally low in infancy; occurs in 0.7 per million children (1-14 years) and 1.2 per million adolescents annually.
Primarily disease of adulthood, peaking in fourth and fifth decades.
Implicated environmental etiologic factor includes ionizing radiation.

Clonal disorder originating within pluripotent hematopoietic stem cells
Characterized by pathognomonic reciprocal translocation t(9;22)(q34;q11),
Translocation creates Philadelphia (Ph1) chromosome,
Results in BCR-ABL1 fusion gene formation,
Generates constitutively active BCR-ABL1 tyrosine kinase
Initiates complex intracellular signal transduction cascade.
Induces strong state of chemotherapy resistance, hyperproliferation, and apoptosis inhibition

Exhibits characteristic triphasic clinical course: chronic phase, accelerated phase, and blast crisis

Encompasses 85% of patients at initial diagnosis.
Features insidious, gradual clinical onset
Nonspecific constitutional symptoms: Fatigue, malaise, weight loss, anorexia, fever
Abdominal findings: Significant splenomegaly causing left upper quadrant pain, hepatomegaly
Median spleen size in children measures 8 cm below costal margin.
Pediatric distinctives: Children manifest proportionally larger spleens and lower hemoglobin levels compared to adults.

Pediatric patients exhibit higher initial white blood cell (WBC) counts (median ~250,000/mm³) compared to adults (80,000-150,000/mm³).
Induces increased blood viscosity.
Decreases central nervous system (CNS) perfusion.
Triggers acute neurologic symptoms.

Marked hyperleukocytosis present
Granulocytes visible at all stages of maturation.
Maturation peaks commonly observed at myelocyte and segmented neutrophilic stages.
Peripheral blasts typically remain <2% during chronic phase.
Basophilia and eosinophilia frequently present.
Platelet counts normal or elevated; thrombocytopenia exceptionally uncommon.
Mild anemia characteristically present.

Demonstrates marked hypercellularity.
Exhibits significant granulocytic proliferation matching peripheral blood maturation.
Blasts comprise <5% of marrow cellularity in chronic phase.
Blast percentage >=10% strictly suggests advanced stage progression.
Mild reticulin fibrosis lacks significant prognostic impact in modern therapeutic era.

Definitive diagnosis requires identification of t(9;22) via karyotyping or fluorescence in situ hybridization (FISH).
BCR-ABL1 fusion transcript quantification required via quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
Bone marrow examination remains essential for complete karyotype analysis and morphologic phase confirmation.

Requires presence of >=1 specific criteria.

Persistent or increasing WBC (>10 x 10^9/L) unresponsive to therapy.
Persistent or increasing splenomegaly unresponsive to therapy.
Persistent thrombocytosis (>1000 x 10^9/L) unresponsive to therapy.
Persistent thrombocytopenia (<100 x 10^9/L) unrelated to therapy.
Basophils >=20% in peripheral blood.
Blasts 10-19% in peripheral blood or bone marrow.
Additional clonal chromosomal abnormalities in Ph1 cells at diagnosis (second Ph, trisomy 8, isochromosome 17q, trisomy 19, complex karyotype).
Any new clonal chromosomal abnormality occurring during therapy.
Provisional TKI response failure (hematologic resistance, cytogenetic resistance, or >=2 BCR-ABL1 mutations)

Represents standard frontline targeted therapy
Targets and inhibits constitutively active BCR-ABL1 tyrosine kinase
Achieves complete hematologic and cytogenetic response.
Drastically reduces rate of progression to accelerated phase or blast crisis.
First-Generation Agent: Imatinib (Gleevec)
Second-Generation Agents (2G-TKIs): Dasatinib, Nilotinib, Bosutinib, Induce faster, deeper molecular remission compared to Imatinib.

Agent	Recommended Pediatric Dose	Administration Guidelines
Imatinib	340 mg/m²/dose	Administered orally once daily
Dasatinib	60 mg/m²/dose	Administered orally once daily.
Nilotinib	230 mg/m²/dose	Administered orally twice daily. Fasting required 2 hours before and 1 hour after dose

Hydroxyurea: Utilized temporarily during chronic phase. Gradually normalizes leukocyte count. Controls disabling or life-threatening symptoms of hyperleukocytosis while awaiting definitive TKI response.

Regular physical examination evaluating spleen size.
Serial complete blood counts with differentials.
Blood qRT-PCR monitored monthly for first 3 months, subsequently every 3 months.

Timepoint	Optimal Response	Warning Indicator	Failure Indicator
3 Months	BCR-ABL1 < 10%	BCR-ABL1 >= 10%
6 Months	BCR-ABL1 < 1%	BCR-ABL1 1-10%	BCR-ABL1 >= 10%
12 Months	BCR-ABL1 < 0.1%	BCR-ABL1 0.1-1%	BCR-ABL1 >= 1%

Suboptimal response mandates screening for specific kinase domain mutations.
Specific mutations dictate alternative TKI selection (e.g., F317L requires Nilotinib/Bosutinib; Y253H requires Dasatinib/Bosutinib).
T315I Mutation: Confers absolute resistance to all first- and standard second-generation TKIs. Mandates use of third-generation agent Ponatinib

Historically represented solely available curative modality prior to TKI advent,
Current utilization heavily restricted due to high efficacy of TKI therapy and significant early transplant-related morbidities

Advanced phase (Accelerated Phase or Blast Phase) presence at initial diagnosis (attempt remission with 2G-TKI first).
Disease progression to Accelerated Phase or Blast Phase during active therapy.
Documented resistance to three sequential TKIs.
Unacceptable, severe intolerance to all available TKI agents.
Presence of T315I mutation (indicated if Ponatinib fails or is unavailable).